curasafehealthcare.com
  • Home
  • About
  • Services
  • Therapeutic Areas
  • Careers
  • Latest News
  • Contact Us
Select Page
Clinical Trials Market | Trends, Growth, Size & Forecast 2024-2031 | Syneos Health, Inc., WuXi AppTec Co., Ltd, Celerion.

Clinical Trials Market | Trends, Growth, Size & Forecast 2024-2031 | Syneos Health, Inc., WuXi AppTec Co., Ltd, Celerion.

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  The Global Clinical Trials Market reached USD 56 640 7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 99 212 0 million by 2031 The clinical trials market is expected to exhibit a …  The Global Clinical Trials Market reached...
Researchers discover race-associated molecular differences in pancreatic tumors

Researchers discover race-associated molecular differences in pancreatic tumors

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic cancer respond to immunotherapies.  Researchers have discovered race-associated molecular differences in tumors that may impact the way...
China Medical University Hospital Joins With AbbVie to Promote Innovative Clinical Trial Collaboration

China Medical University Hospital Joins With AbbVie to Promote Innovative Clinical Trial Collaboration

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  Li-Yuan Bai, M.D., M.M.S., Ph.D.  Li-Yuan Bai, M.D., M.M.S., Ph.D. 
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for…  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced...
Takeda’s Diversity Strategy Pays Off For Phase 3 Trial

Takeda’s Diversity Strategy Pays Off For Phase 3 Trial

by palligoelme@gmail.com | Mar 12, 2025 | Uncategorized

​  LaShell Robinson, head of global feasibility and trial equity at Takeda explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics.  
« Older Entries
Next Entries »

Recent Posts

  • School Nurse-Led Help-Seeking Program in Middle School Students
  • Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
  • AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
  • Measuring Reliability of Spine Mobilization in Low Back Pain
  • Biceps Femoris Short Head (BiFeS) Block and Adductor Canal Block for Postoperative Analgesia Following Total Knee Arthroplasty

Recent Comments

No comments to show.

Curasafe healthcare solutions Pvt. Ltd. provides comprehensive services including safety program oversight, risk management, and regulatory compliance.

Important Links

  • Home
  • Contact Us
Connect With Us

Contact


711, Shivalik Satyamev, Bopal Ambli Junction, Bopal, Ahmedabad, Daskroi, Gujarat, India, 380058.


info@curasafehealthcare.com



(+91) 97803 81065

Copyright © 2025 Curasafehealthcare ®